Thoratec Unloads Dx Equipment Unit To Danaher To Help Fund VAD Efforts
This article was originally published in The Gray Sheet
Executive Summary
Thoratec's divestiture of hospital and home diagnostic equipment maker International Technidyne Corp. to Danaher for up to $136 million will allow greater focus on the firm's core ventricular assist device business
You may also be interested in...
Thoratec Q2 Sales Up 37%; Plans To Divest ITC To Danaher Fall Through
Thoratec's second-quarter sales jumped 37% over the year-ago period, to $95.1 million, on continued adoption of the HeartMate II left ventricular assist system as both destination and bridge-to-cardiac transplant therapy, the firm reported July 29
Thoratec Q2 Sales Up 37%; Plans To Divest ITC To Danaher Fall Through
Thoratec's second-quarter sales jumped 37% over the year-ago period, to $95.1 million, on continued adoption of the HeartMate II left ventricular assist system as both destination and bridge-to-cardiac transplant therapy, the firm reported July 29
Transplant Experts Urge Caution As CMS Weighs Expanded LVAD Coverage
Groups representing artificial heart transplant providers and researchers are advising CMS to make sure there is adequate clinical evidence before the agency expands Medicare coverage for left ventricular assist devices as a destination therapy for New York Heart Association Class IIIB patients